Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes.

Trial Profile

Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Lixisenatide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LIRA-LIXI
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Jun 2016 Results published in the Diabetes Care
    • 16 Sep 2015 According to Novo Nordisk media release, results were presented in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top